1. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density
- Author
-
Douglas Kitch, Grace A. McComsey, Belinda Ha, Paul E. Sax, Kristine M. Erlandson, Pablo Tebas, Eric S. Daar, Nasreen C. Jahed, Kathleen Melbourne, and Camlin Tierney
- Subjects
Adult ,Male ,Radiography, Abdominal ,medicine.medical_specialty ,Efavirenz ,Tenofovir ,Immunology ,Urology ,HIV Infections ,Article ,law.invention ,chemistry.chemical_compound ,Absorptiometry, Photon ,Randomized controlled trial ,Bone Density ,law ,Linear regression ,medicine ,Humans ,Immunology and Allergy ,Prospective Studies ,Prospective cohort study ,Bone mineral ,business.industry ,Body Weight ,Middle Aged ,Antiretroviral therapy ,Surgery ,Infectious Diseases ,Anti-Retroviral Agents ,chemistry ,Body Composition ,HIV-1 ,Lean body mass ,Female ,Tomography, X-Ray Computed ,business ,medicine.drug - Abstract
OBJECTIVE To compare the effect that initiating different antiretroviral therapy (ART) regimens has on weight, BMI, and lean body mass (LBM) and explore how changes in body composition are associated with bone mineral density (BMD). METHODS A5224s was a sub-study of A5202, a prospective trial of 1857 ART-naive participants randomized to blinded abacavir-lamivudine (ABC/3TC) or tenofovir DF-emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV/r). All participants underwent dual-energy absorptiometry (DXA) and abdominal computed tomography for body composition. Analyses used two-sample t-tests and linear regression. RESULTS A5224s included 269 participants: 85% men, 47% white non-Hispanic, median age 38 years, HIV-1 RNA 4.6 log10 copies/ml, and CD4 cell count 233 cells/μl. Overall, significant gains occurred in weight, BMI, and LBM at 96 weeks post-randomization (all P
- Published
- 2013